Explore the Agenda

7:50 am Check In & Morning Coffee

8:50 am Chair’s Opening Remarks

Chief Technology Officer, Beam Therapeutics

Turbocharging mRNA Innovation & Clinical Strategy to Advance the Future of Vaccines & Therapeutics for Patients Faster

9:00 am CEO Think Tank: Unlocking the Next Wave of mRNA-Based Vaccines, Therapeutics & Platforms to Develop Better mRNA Drugs Towards Clinical Reality

President & CEO, Arcturus Therapeutics
Chief Scientific Officer, RNAvate
Chief Executive Officer, Radar Therapeutics
Chief Technology Officer, Beam Therapeutics
Chief Executive Officer, CureVac
President and Chief Executive Officer, Orbital Therapeutics
Chief Executive Officer, Replicate Bioscience

10:00 am Panel Discussion: Harnessing the Potential of mRNA & Circular RNA Technology as a Tool to Advance In Vivo Engineering Cell & CAR-T Therapy

Chief Scientific Officer, Orbital Therapeutics
Co founder - Head of Discovery, InnDura Therapeutics
Co-Founder & CEO, Byterna Therapeutics
Chief Scientific Officer, Sail Biomedicines
Chief Executive Officer, Orna Therapeutics
Founder, Able Sciences
Co-Founder and VP/Head of Research, Capstan Therapeutics

11:00 am Morning Break & Speed Networking

Discovery

Optimizing Novel mRNA-LNP Design & Platform Strategies to Accelerate Discovery Timelines – Chair

Director, AstraZeneca
Director, Editas Medicine

11:30 am Circular RNA: From Promise to Reality

Chief Scientific Officer, RNAvate

12:00 pm RNA Quality Control: A Sequencing-First Perspective

Head Associate Director, Platform, Eclipse Bio

12:30 pm Recent Progress in mRNA-Based Targeted Protein Degrader Development

Chief Executive Officer (Research & Development), Genexine
Pre-Clinical Development
Clinical
Manufacturing & CMC

1:00 pm Lunch & Networking Break

Discovery

Discovering Novel mRNA Vaccine & Therapeutic Proof-of-Concepts to Shine Light on Promising New Applications Across Disease Indications – Chair

Director, AstraZeneca

2:00 pm Selective Agonism of Specific Pattern Recognition Receptors to Generate Next Generation Safe & Effective mRNA Vaccines & Therapeutics

President, Chairman & Chief Executive Officer, Celestial Therapeutics

2:30 pm mRNA Lipid Nanoparticles for the Treatment of Obesity

Chief Executive Officer, Grann Pharmaceuticals
Pre-Clinical Development
Clinical
Manufacturing & CMC

3:00 pm Afternoon Break & Poster Session

Discovery

Accelerating Novel Target Discovery for Targeted mRNA Therapeutics to Widen mRNA Application – Chair

Director, AstraZeneca

4:00 pm Exosome Inhibitors of Cardiac Apoptosis Induced by STEMIN & YAP5SA ModeRNA, the Next Breakthrough in Treating Heart Failure

Chief Scientific Officer, Animatus Biosciences

4:30 pm Targeted mRNA Therapeutics

Assistant Professor- Pharmacology, University of Pennsylvania
Pre-Clinical Development
Clinical
Manufacturing & CMC

5:00 pm End of Conference Day One